{"disease":{"id":"her2-positive-metastatic-breast-cancer","name":"her2 positive metastatic breast cancer"},"drugs":{"marketed":[{"drug_id":"trastuzumab-emtansine","indication_name":"Treatment of HER2-positive unresectable or metastatic breast cancer in patients who have received prior anti-HER2-based therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Kadcyla","generic_name":"trastuzumab-emtansine","company_name":"Roche","drug_phase":"marketed","molecular_target":"Receptor tyrosine-protein kinase erbB-2","drug_class":"Antibody-drug conjugate","quality_score":71,"revenue":"900","mechanism":"Trastuzumab emtansine is a HER2-targeted antibody-drug conjugate that works by binding to the HER2 receptor and releasing a cytotoxic agent."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05838066","title":"Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":880,"lead_sponsor_name":"Shanghai JMT-Bio Inc.","has_results":false},{"nct_id":"NCT06305702","title":"Real-world Study of Inetetamab in HER2-positive Metastatic Breast Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":500,"lead_sponsor_name":"Liaoning Cancer Hospital & Institute","has_results":false},{"nct_id":"NCT05424835","title":"A Trial of SHR-A1811versus Pyrotinib in Combination With Capecitabine in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":381,"lead_sponsor_name":"Jiangsu HengRui Medicine Co., Ltd.","has_results":false},{"nct_id":"NCT05042791","title":"A Study of Pyrotinib Plus Capecitabine Combined With SRT in HER2+ MBC With Brain Metastases","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":362,"lead_sponsor_name":"Jiangxi Provincial Cancer Hospital","has_results":false},{"nct_id":"NCT06278870","title":"Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":312,"lead_sponsor_name":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","has_results":false},{"nct_id":"NCT02514681","title":"A Phase III Trial of Pertuzumab Retreatment in Previously Pertuzumab Treated Her2-Positive Advanced Breast Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":226,"lead_sponsor_name":"Japan Breast Cancer Research Group","has_results":false},{"nct_id":"NCT06551116","title":"QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Abramson Cancer Center at Penn Medicine","has_results":false},{"nct_id":"NCT05868226","title":"PRE-I-SPY Phase I/Ib Oncology Platform Program","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":124,"lead_sponsor_name":"QuantumLeap Healthcare Collaborative","has_results":false},{"nct_id":"NCT06714617","title":"Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":120,"lead_sponsor_name":"SystImmune Inc.","has_results":false},{"nct_id":"NCT02605915","title":"Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":98,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT03691051","title":"A Study of Pyrotinib Plus Capecitabine in Patients With Brain Metastases From HER2-positive Metastatic Breast Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":78,"lead_sponsor_name":"Henan Cancer Hospital","has_results":false},{"nct_id":"NCT02658734","title":"A Study of Trastuzumab Emtansine in Indian Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Treatment With Trastuzumab and a Taxane","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":70,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT07503717","title":"SURVEY-CNS: A Feasibility Study of Randomising Women and Men With HER2-Positive Metastatic Breast Cancer to Central Nervous System Surveillance Versus No Surveillance","phase":"NA","overall_status":"RECRUITING","enrollment_count":69,"lead_sponsor_name":"Royal College of Surgeons, Ireland","has_results":false},{"nct_id":"NCT05621434","title":"A Study to Evaluate Inetetamab + Pyrotinib + Chemotherapy in Previously Untreated HER2-Positive Metastatic Breast Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":63,"lead_sponsor_name":"Fujian Medical University","has_results":false},{"nct_id":"NCT02025192","title":"A Study of Tucatinib (ONT-380) Combined With Capecitabine and/or Trastuzumab in Patients With HER2+ Metastatic Breast Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Seagen Inc.","has_results":false},{"nct_id":"NCT05188495","title":"Trastuzumab(Henlius®) Combined With Pertuzumab(Perjeta®) and Chemotherapy in Chinese Patients With Her2-Positive Metastatic Breast Cancer Previously Treated With Trastuzumab","phase":"","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"Peking University Cancer Hospital & Institute","has_results":false},{"nct_id":"NCT04692831","title":"Testing a New Imaging Agent to Identify Cancer","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":60,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT06299852","title":"Stereotactic Radiation Therapy for HE2-positive Oligometastatic Breast Cancer","phase":"NA","overall_status":"UNKNOWN","enrollment_count":58,"lead_sponsor_name":"N.N. Petrov National Medical Research Center of Oncology","has_results":false},{"nct_id":"NCT07182721","title":"SKB264 Plus Inetetamab in HER2-Positive Metastatic Breast Cancer Patients Progressing After T-DXd Treatment","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":48,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT04681287","title":"Exploratory Study of Advanced Breast Cancer in HER2 Positive Patients With Failure of Multi-line Therapy Treated by Combination of Inetetamab (Cipterbin) + PD-1 Inhibitor Combined With Utidelone.","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":46,"lead_sponsor_name":"Henan Cancer Hospital","has_results":false},{"nct_id":"NCT06663748","title":"ARX788 in HER2-positive Metastatic Breast Cancer Patients","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":44,"lead_sponsor_name":"Henan Cancer Hospital","has_results":false},{"nct_id":"NCT05230810","title":"Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":40,"lead_sponsor_name":"Criterium, Inc.","has_results":false},{"nct_id":"NCT05252546","title":"Effect of Montmorillonite Power or Loperamide on the Pharmacokinetics of Pyrotinib in Healthy Subjects","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"Jiangsu HengRui Medicine Co., Ltd.","has_results":false},{"nct_id":"NCT05018702","title":"ARX788 in HER2-positive Breast Cancer Patients With Brain Metastases","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":32,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT05036252","title":"Study of Cardiopulmonary Exercise Testing in Women Who Have HER2-Positive Breast Cancer With Mild Cardiotoxicity","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":23,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT05959291","title":"Discontinuation of Maintenance HER-2 Directed Therapy in Long-Term Survivors of Metastatic HER-2 Positive Breast Cancer","phase":"NA","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"University of Miami","has_results":false},{"nct_id":"NCT05555251","title":"BI-1607 in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":18,"lead_sponsor_name":"BioInvent International AB","has_results":false},{"nct_id":"NCT04398108","title":"A Study to Evaluate the Pharmacokinetics of Margetuximab in Chinese Patients With HER2+ MBC","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":16,"lead_sponsor_name":"Zai Lab (Shanghai) Co., Ltd.","has_results":false},{"nct_id":"NCT05583110","title":"Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast Cancer","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":13,"lead_sponsor_name":"Spanish Breast Cancer Research Group","has_results":false},{"nct_id":"NCT04319757","title":"ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"Acepodia Biotech, Inc.","has_results":false},{"nct_id":"NCT04778982","title":"Study of KN026 in Combination With Palbociclib and Fulvestrant in Patients With Advanced Breast Cancer","phase":"","overall_status":"TERMINATED","enrollment_count":4,"lead_sponsor_name":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","has_results":false},{"nct_id":"NCT02598427","title":"Intrathecal Pertuzumab and Trastuzumab in Patients With New Untreated Asymptomatic or Low Symptomatic Brain Metastasis in HER2 Positive Breast Cancer","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":1,"lead_sponsor_name":"Kimberly Blackwell","has_results":false},{"nct_id":"NCT04602117","title":"ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer","phase":"PHASE1","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"QuantumLeap Healthcare Collaborative","has_results":false}],"total":33},"guidelines":[],"source":"Drug Landscape verified database"}